As attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natural Biocon (India) Ltd announced its audited standalone financial results for the quarter and full year ended March 31, 2025. Full-year revenue from operations fell sharply to ₹834.81 lakhs from ₹1,353.37 lakhs in FY24, a decline of roughly 38%. Full-year net profit dropped about 71% to ₹4.46 lakhs (from ₹15.27 lakhs), with EPS at ₹0.02 vs ₹0.13. Q4 alone was a weak quarter, posting a loss of ₹48.62 lakhs against a profit of ₹5.86 lakhs in the year-ago quarter. The company raised ₹1,945.35 lakhs through a share capital issue during the year, and total assets more than doubled to ₹3,852.22 lakhs, mainly due to fresh investments of ₹2,112.37 lakhs and capital work-in-progress of ₹328.99 lakhs. The statutory auditor M/s Mayur Shah & Associates issued an unmodified (clean) audit opinion.
The sharp revenue contraction and quarterly loss signal weak core operations, which is negative for near-term sentiment. However, the fresh equity infusion and clean audit opinion provide some comfort on financial stability. Shareholders should watch whether the new investments and capital projects translate into revenue recovery in FY26.